Filing Flows › Immucell (ICCC) › Q3 2025
Immucell (ICCC) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 13, 2025
Immucell (ICCC) reported revenue of $5.5M for the third quarter 2025 (Q3 2025), -8% from a year earlier and -15% from the quarter before. Operating margin was 0.4%, net loss $140K (2.5% of revenue).
Immucell, Q3 2025: revenue $5.5M (-8% year over year), operating margin 0.4%, net loss $140K, operating cash flow −$1.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5.5M | -15% | -8% |
| Operating profit | $20K | -96% | — |
| Net earnings | −$140K | -128% | — |
| Operating cash flow | −$1.2M | -174% | — |
What changed
Revenue was $5.5M in Q3 2025, down 8% year over year and down 15% from the previous quarter.
Gross margin was 42.9%, up 16.6 points from a year earlier. Operating profit was $20K, a 0.4% margin (up 9.9 points year over year). Operating expenses grew 9% against a revenue fall of 8%. The fastest-growing cost line was General & admin (+38%). The quarter ended with a net loss of $140K, after a profit of $502K the previous quarter. Net interest and other expense of $155K was the main reason.
Operating cash flow was −$1.2M. Non-cash charges added back $709K of depreciation and amortization and $73K of share-based compensation. Working capital and other items used $1.8M. Capital expenditures of $594K exceeded it, leaving free cash flow of −$1.8M.
Questions
What was Immucell's revenue in the third quarter 2025?
Immucell (ICCC) reported revenue of $5.5M for the third quarter 2025 (Q3 2025), -8% from a year earlier and -15% from the quarter before.
Was Immucell profitable in the third quarter 2025?
Operating profit was $20K (0.4% of revenue) and net loss $140K.
Source: Immucell 10-Q on SEC EDGAR.